Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.090
-0.050 (-1.59%)
Feb 21, 2025, 4:00 PM EST - Market closed
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
75
Market Cap
260.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AVIR News
- 6 weeks ago - Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process - Business Wire
- 2 months ago - Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewsWire
- 2 months ago - After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Benzinga
- 2 months ago - Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript - Seeking Alpha